peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

RAS peptide

Angiotensin 1-7

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

The peptide ligand is named angiotensin-(1-7).

Sources for this introduction: [1]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

The peptide ligand is named angiotensin-(1-7).

Sources[1]iuphar-commentsIUPHAR ligand commentaryAngiotensin (1-7) is a naturally occurring peptide[1]iuphar-commentsIUPHAR ligand commentaryAngiotensin (1-7) is a naturally occurring peptide[2]iuphar-ligandangiotensin-(1-7)Name: angiotensin-(1-7)[2]iuphar-ligandangiotensin-(1-7)Name: angiotensin-(1-7)[3]pubmedNeurovascular unit dysfunction in vascular cognitive impairment: Mechanisms, biomarkers, and translational strategies.the glycosylated angiotensin-(1-7) analogue PNA5
Source records
5
Independent studies
3

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Angiotensin (1-7) is a naturally occurring peptide”

    IUPHAR ligand commentary · General comments

    iuphar-comments:582:53c83d9553e3:53c83d9553e3
  2. supports · Source-backed record
    “Angiotensin (1-7) is a naturally occurring peptide”

    IUPHAR ligand commentary · General comments

    iuphar-comments:582:53c83d9553e3:53c83d9553e3
  3. supports · Source-backed record
    “Name: angiotensin-(1-7)”

    angiotensin-(1-7) · Identity and approval

    iuphar-ligand:582:64222f53c390:64222f53c390
  4. supports · Source-backed record
    “Name: angiotensin-(1-7)”

    angiotensin-(1-7) · Identity and approval

    iuphar-ligand:582:64222f53c390:64222f53c390
  5. supports · Source-backed record
    “the glycosylated angiotensin-(1-7) analogue PNA5”

    Neurovascular unit dysfunction in vascular cognitive impairment: Mechanisms, biomarkers, and translational strategies. · Abstract

    pubmed:42105801:54d47f50f7fd:54d47f50f7fd

Identity

TXA127 is named as a formulated pharmaceutical version of the peptide angiotensin (1-7).

Sources[1]iuphar-commentsIUPHAR ligand commentaryA pharmaceutical formulation of angiotensin (1-7) known as a TXA127[1]iuphar-commentsIUPHAR ligand commentaryA pharmaceutical formulation of angiotensin (1-7) known as a TXA127
Source records
2
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “A pharmaceutical formulation of angiotensin (1-7) known as a TXA127”

    IUPHAR ligand commentary · Clinical use

    iuphar-comments:582:53c83d9553e3:53c83d9553e3
  2. supports · Source-backed record
    “A pharmaceutical formulation of angiotensin (1-7) known as a TXA127”

    IUPHAR ligand commentary · Clinical use

    iuphar-comments:582:53c83d9553e3:53c83d9553e3

How does it work?

Target, response, and disposition.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

What has been studied?

What the evidence says.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, effect, interaction, mechanism, regulatory, safety
  • 99 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (65), assurance_score_below_0.72 (32), current_regulatory_source_required (21), extraction_ambiguity (61), high_risk_requires_regulatory_or_two_independent_sources (33), no_direct_support (93), proposal_not_staged (6)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. IUPHAR ligand commentary ↗

    iuphar-comments · published 2026-08-25 · retrieved 2026-08-25T22:43:25Z

  2. angiotensin-(1-7) ↗

    iuphar-ligand · published 2026-08-25 · retrieved 2026-08-25T22:43:25Z

  3. Neurovascular unit dysfunction in vascular cognitive impairment: Mechanisms, biomarkers, and translational strategies. ↗

    pubmed · published 2026-09-01 · retrieved 2026-08-25T22:43:25Z

Publication history and provenance

Version 5 · Automated assessment · 2026-08-25T22:43:25Z

a15947d95993272641d712216f48ecb782e1d0c0a38ede03f4f9d2e5413d5fe5